RET/PTC rearrangements, implicated in HT, activate pathways that induce both HT and the expression of genes like CXCL5 and CXC chemokine receptor 2 (CXCR2), linked to inflammation and tumor invasion (21). The gene discussed is CXCR2; the disease is hematocrit.